Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Neoplasms 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Lymphoma 1

Interventions

pembrolizumab 5Cyclophosphamide 5Nivolumab 4Psychiatric Rehabilitation 3Paclitaxel 3Flow Cytometry 3Filgrastim 3valspodar 2sargramostim 2fludarabine 2epacadostat 2durvalumab 2atezolizumab 2aldesleukin 2Surveys and Questionnaires 2Microarray Analysis 2Methylprednisolone 2Melphalan 2Interleukin-2 2Immunologic Techniques 2Early Intervention, Educational 2Dexamethasone 2Dasatinib 2Carboplatin 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Miransertib × Gynecologic × Clear all
NCT01473095 2017-10-23

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
120 enrolled
GynecologicLymphoid

Lymphoma, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡